Psoriasis

Below is a list of our psoriasis studies that are currently enrolling.

A Phase 3, Randomized, Active-controlled Study of Risankizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis

Population: Children aged six to eleven years old
Study Condition: Moderate to severe plaque psoriasis
Study Design: The purpose of this study is to evaluate pharmacokinetics, safety, and effectiveness of investigational drug risankizumab in a pediatric population with moderate to severe plaque psoriasis. Study duration will be up to approximately 65 weeks, consisting of a screening period of up to 35 days, a 52-week study treatment period, and a 20-week follow-up call. Subjects that meet all eligibility criteria will complete 9 study visits on site and receive risankizumab at Weeks 0, 4, 16, 28, and 40. A follow-up call will take place 20 weeks after the last dose of study drug if the subject does not enroll into the long-term extension study.
Compensation may be provided upon study participation

Please contact Dr. Caroline Porter for more information regarding ongoing psoriasis studies.